The only study that examined the association of both measures (sarcopenia and BMI) with outcomes in patients with NSCLC and EGFR mutation was a retrospective study of 167 patients who received gefitinib, erlotinib, or afatinib as a first or later line therapy (89). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.